Related Experiment Videos
[Pregnancy risks in acquired heart diseases].
V Stangl1, G Baumann, K Stangl
1Medizinische Klinik mit Schwerpunkt Kardiologie, Angiologie, Pneumologie Charité der Humboldt-Universität, Campus Mitte, Berlin Schumannstr. 20/21 10117 Berlin. verena.stangl@charite.de
Zeitschrift Fur Kardiologie
|May 26, 2001
Summary
Managing pregnancies with acquired heart disease requires understanding hemodynamic changes and risks. Critical periods, like weeks 30-32 and the peripartal phase, need close interdisciplinary care for maternal and fetal well-being.
Area of Science:
- Cardiology
- Maternal-Fetal Medicine
- Obstetrics
Context:
- Pregnancy significantly alters cardiovascular physiology.
- Acquired heart disease presents unique challenges during gestation.
- Maternal and fetal outcomes depend on careful management of cardiac conditions.
Purpose:
- To outline the hemodynamic adaptations during pregnancy and their impact on pre-existing heart conditions.
- To identify critical management periods and therapeutic strategies for pregnant patients with heart disease.
- To discuss risks and management of specific cardiac conditions, including valvular disease, cardiomyopathy, and dissections.
Summary:
- Pregnancy necessitates understanding hemodynamic shifts impacting acquired heart disease.
- Critical periods (weeks 30-32, peripartal phase) require intensive interdisciplinary support.
- Management strategies vary for valvular stenosis, insufficiency, peripartal cardiomyopathy, and dissections, prioritizing maternal-fetal safety.
- Vaginal delivery is feasible for mild/moderate stenosis; C-section for severe cases. ACE inhibitors and AT1 antagonists are contraindicated; hydralazine, nitrates, or calcium antagonists are alternatives for afterload reduction.
Impact:
- Provides guidance for optimizing pregnancy outcomes in women with heart disease.
- Highlights the importance of individualized, interdisciplinary care.
- Informs clinical decision-making regarding delivery modes and pharmacotherapy.
- Contributes to reducing maternal and fetal morbidity and mortality associated with cardiac complications in pregnancy.